Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nidaa Khamousia

Internal Medicine Maumee, OH Medical Doctor

NPI 1184687014 CMS profile 234480

6450 Wheatstone Ct, Maumee, OH 43537

Open in the dashboard

General payments

$8,141

242 records reported · program years 2019–2025

Research payments

$4,923

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nidaa Khamousia of Maumee, OH is reported in the CMS Open Payments database as having received $8,141 across 242 general payments and $4,923 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $383 22
2024 General $1,026 42
2023 General $496 26
2022 General $588 27
2022 Research $3,377 9
2021 General $473 25
2020 General $2,006 47
2019 General $3,168 53
2019 Research $1,545 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nidaa Khamousia
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Nidaa Khamousia were reported at $383. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Nidaa Khamousia Internal Medicine median Middle half National median
2019 $3,168 $159 $48–$570 $163
2020 $2,006 $119 $33–$402 $114
2021 $473 $135 $37–$521 $132
2022 $588 $141 $42–$496 $149
2023 $496 $149 $45–$519 $160
2024 $1,026 $154 $47–$537 $164
2025 $383 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca UK Limited $1,338 7 payments
  2. Novo Nordisk AS $1,288 4 payments
  3. Radius Health, Inc. $1,280 11 payments
  4. Novo Nordisk Inc $779 47 payments
  5. AstraZeneca Pharmaceuticals LP $655 28 payments
  6. Amgen Inc. $273 18 payments
  7. AbbVie, Inc. $210 9 payments
  8. Lilly USA, LLC $207 14 payments
  9. Amarin Pharma Inc. $194 9 payments
  10. Exact Sciences Corporation $179 11 payments
  11. Other $1,739 84 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,404 235 payments
  2. Travel and Lodging $2,731 6 payments
  3. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $570 22 payments
  2. Ozempic $415 28 payments
  3. RYBELSUS $276 18 payments
  4. EVENITY $192 13 payments
  5. Cologuard Collection Kit $179 11 payments
  6. Korlym $158 3 payments
  7. Prolia $151 10 payments
  8. FreeStyle Libre 3 $144 7 payments
  9. WATCHMAN Access System $144 1 payment
  10. Kerendia $140 4 payments
  11. Other $2,958 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk AS $3,377 9 payments
  2. Sanofi US Services Inc. $1,248 3 payments
  3. Eli Lilly and Company $297 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

3,262

Median for Internal Medicine: 777

Drug cost

$237,764

Median for Internal Medicine: $73,373

Branded share of claims

19.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 90 $134,320
Mounjaro Tirzepatide Brand 23 $39,744
Farxiga Dapagliflozin Propanediol Brand 20 $21,257
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 31 $5,041
Rosuvastatin Calcium Generic 294 $4,418
Atorvastatin Calcium Generic 314 $3,436
Levothyroxine Sodium Generic 244 $3,365
Ezetimibe Generic 31 $1,777
Synthroid Levothyroxine Sodium Brand 55 $1,529
Losartan Potassium Generic 175 $1,382

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$68,981

Of which drugs: $7,144

Medicare patients

181

Average age 73

Services billed

1,197

161 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 51%
Osteoporosis 34%
Diabetes 28%
Ischemic heart disease 27%
Cancer 24%
Chronic kidney disease 21%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 13 13 $3,751
Vaccine for influenza for injection into muscle 90653 Office 35 35 $2,864

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $115
$115 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $106
$106 20 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $84
$84 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $51
$51 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $43
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record